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Abstract
Background: Hypothyroidism is a common endocrine condition. There is evidence to suggest that, for a
proportion of sufferers, the standard medical treatment does not completely reverse the constitutional and
neuropsychiatric symptoms brought about by this condition. The management of hypothyroidism follows a
biomedical model with little consideration given to alternative management approaches. There exists anecdotal
evidence and case reports supporting the use of a biopsychosocial-based intervention called Neuro-Emotional
Technique (NET) for this population. The aim of this study was to explore the potential short-medium term clinical
efficacy and safety of NET for individuals with primary hypothyroidism.
Design
Placebo-controlled, blinded, parallel groups, randomized trial.
Methods: Ninety adults with a diagnosis of primary hypothyroidism were recruited from Sydney, Australia. Blinded
participants were randomized to either the NET or placebo group and received ten intervention sessions over a six
week period. The primary outcome involved the measurement of states of depression using the DASS-42
questionnaire. Secondary outcomes included thyroid function, thyroid autoimmunity testing, SF-36v2 questionnaire,
resting heart rate and temperature measurement. Outcomes were obtained at baseline, seven weeks and six
months. Questionnaires were completed at the private clinics, and serum measures were obtained and analysed at
commercial pathology company locations. Heart rate and temperature were also measured daily by participants.
Linear mixed-effects models were used to analyse the continuous outcomes. Unadjusted odds ratios with 95%
confidence intervals were calculated for the binary outcomes.
Results: Participants were randomly allocated to the NET (n=44) and placebo (n=46) groups. A proportion of the
sample displayed neuropsychiatric disturbances and alterations in quality of life measures at baseline. There were
no statistically significant or clinically relevant changes in the primary or secondary outcomes between the NET and
placebo groups at time seven weeks or six months. There were a few short-lived minor adverse events reported in
both the NET and placebo groups that coincided with the application of the intervention.
Conclusions: The application of the NET intervention appears to be safe, but did not confer any clinical benefit to
the participants in this study and is unlikely to be of therapeutic use in a hypothyroid population.
Clinical trials registration number: Australian and New Zealand Clinical Trials Registry Number: 12607000040460.
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Background
Hypothyroidism is a common endocrine condition that af-
fects a significant proportion of individuals worldwide.
Using data from a community-based sample from an
iodine-replete region in Western Australia, it is estimated
0.54 % of Australians suffer from this condition [1]. Fe-
males are more likely to develop hypothyroidism compared
to males (Prevalence - women 1–2 % and men 0.1 %) [1–
3]. The primary variant of this disease accounts for the vast
majority (99 %) of cases. Primary hypothyroidism is due to
a failure of the thyroid gland and results in a deficient con-
centration of thyroid hormones in the serum. The most
common cause of this glandular failure is an autoimmune
condition called Hashimoto’s thyroiditis [4, 5]. The symp-
toms of overt hypothyroidism are based on deficits in
energy metabolism and thermogenesis. Consequently,
patients present with a constellation of physical and
neuropsychiatric findings (i.e. musculoskeletal complaints,
depression, free-floating anxiety, memory deficits) [6, 7],
and in cases of thyroid autoimmunity, formation of anti-
bodies to thyroglobulin (Tg) and thyroid peroxidase
(TPO) [4]. The gold-standard treatment for primary
hypothyroidism is relatively straightforward and involves
supplementation of one of the deficient hormones using a
synthetic version of the thyroid hormone - thyroxine. This
synthetic analogue is called levothyroxine (LT4). The treat-
ment dosage of thyroid hormone is gradually titrated up-
wards until an individual displays normal physiological
concentrations of free-thyroxine (FT4) and thyroid stimu-
lating hormone (TSH) in the serum. Put simply, the prod-
uct of the dysfunctional gland is ‘topped up’ using an
exogenous source of thyroid hormone, with the required
dose being modified according to the patient’s FT4 and
TSH assay results. The patient continues with this program,
combined with regular check-ups, either for the rest of their
lives or until some event occurs (e.g. pregnancy) that war-
rants a change in the patient’s thyroxine dosage. The nor-
mal reference range for TSH is 0.4–3.5 mIU/L. Patients
receiving thyroid hormone replacement are given sufficient
quantities of thyroxine to maintain their serum TSH con-
centrations within an ideal range (0.5–2.0 mIU/L) [8].
While the treatment regimen for primary hypothyroidism
is regarded by many as one of the major ‘success stories’ of
medicine [9], there is evidence to suggest that a small pro-
portion of individuals with managed-hypothyroidism con-
tinue to display the overt manifestations of the disease
despite normalised blood test results - indicating a euthyr-
oid state [10–12]. Furthermore, the decreased quality of life
(QOL) that is observed in hypothyroid individuals does not
always improve with the appropriate treatment [10, 13–15].
Large community-based studies [14, 16, 17] demonstrate
that there is neurocognitive and psychological impairment
in individuals with hypothyroidism. Unfortunately, in some
patients, the restoration of normal thyroid hormone levels
through thyroxine supplementation only partially amelio-
rates these impairments.
One of the main reasons for the persistence of symptoms
in euthyroid patients with hypothyroidism is the under-
lying autoimmune process. Patients with Hashimoto’s
thyroiditis are more likely to experience higher symptom
loads with reference to mood and quality of life, despite be-
ing euthryoid [18]. Furthermore, it is not uncommon for
patients with Hashimoto’s thyroiditis to have other comor-
bid autoimmune conditions e.g. rheumatoid arthritis [19].
The presence of these additional conditions contributes to
an increased symptom load that is unaltered by the restor-
ation of normal thyroid hormone concentrations in the
serum. McDermott [20] suggests that a complete blood
count, serum 25-hydroxyvitamin D, erythyrocyte sedimen-
tation rate, sleep apnoea testing, celiac disease testing as
well as a metabolic, hormonal, psychological, and lifestyle
assessment should be performed in euthyroid patients with
persistent symptoms. This strategy can be used to rule out
comorbid medical conditions and/or to identify modifiable
risk factors.
Researchers [21, 22] have identified polymorphisms in
genes that encode for the deiodinase enzymes in patients
with hypothyroidism. There is preliminary evidence to sug-
gest [23] that patients with polymorphisms in the Deiodi-
nase Type II gene may display poorer outcomes on
levothyroxine therapy compared with patients receiving
preparations containing both levothyroxine and liothyro-
nine (synthetic T3). However, this combination therapy has
not proven superior to standard monotherapy [24–27].
With respect to therapeutic intervention, very little at-
tention has been given to the main cause of primary
hypothyroidism – thyroid autoimmunity [28]. The main
reason for this is that the pathogenesis of thyroid auto-
immunity is not fully understood [28]. Current research
suggests that autoimmune thyroid disease may result
from complex interactions between environmental trig-
gers and genetic susceptibilities [29–32]. The purported
environmental triggers include: iodine excess [33, 34],
selenium deficiency [35], fetal microchimerism [36, 37],
infections [38, 39], and stress [40]. With regard to stress as
an environmental trigger, associations have been reported
most frequently with Graves’ disease [41–46].
Psychological stress, via alterations in the sympathetic-
adrenal-medullary (SAM) axis and the hypothalamic-
pituitary-adrenal (HPA) axis, can have deleterious effects
on the endocrine and immune systems [47–49]. With
respect to the immune system, chronic stress shifts the
balance of the cell-mediated immune response, specific-
ally suppressing the subset of T-helper lymphocytes
called the Th1 cells [49]. This suppression has a permis-
sive effect on the production of another subset of T-
helper cells called Th2 cells [50]. This shift in the Th1/
Th2 balance has been observed in certain autoimmune
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diseases such as Systemic Lupus Erythematosus and
Graves’ disease [50, 51]. As a hyperactivation of the HPA
axis is a common response to most forms of stress [52],
it would be logical to expect a shift to Th2 dominance
and a resultant increase in cases of Graves’ disease in
genetically susceptible individuals who are stressed. The
contribution of stress to Hashimoto’s thyroiditis however
is less intuitive. There is some research to suggest that
there is HPA axis hypoactivation in patients with
hypothyroidism [53, 54]. While hyperactivation of the
HPA axis leads to a suppression of Th1 dominant states,
a hypoactivation of the HPA axis promotes Th1 dominant
states [50]. Autoimmune conditions such as rheumatoid
arthritis, Hashimoto’s thyroiditis, multiple sclerosis and
diabetes type I are T-cell mediated diseases, however they
are thought to occur due to these Th1 dominant states
[50, 55, 56]. Hypoactivation of the HPA axis has also been
observed in patients with a history of childhood abuse
[57] and post-traumatic stress disorder [58], which may
be an adaptive response to intense or prolonged psycho-
logical stress. The role of stress in Hashimoto’s thyroiditis
has received far less attention compared to the role of
stress in Graves’ disease [59]. While it is biologically
plausible that stress could play an etiological role in gen-
etically susceptible individuals, there are no reported posi-
tive associations between stress and autoimmune induced
hypothyroidism in the current literature [60–62].
Anecdotal evidence and case reports [63, 64] exist that
suggest that a biopsychosocial-based intervention called
Neuro-Emotional Technique (NET), which is described
as a mind-body stress reduction intervention [65, 66],
may be useful in the treatment of hypothyroidism. This
technique has been taught and used by practitioners of
varying backgrounds since the late 1980s [66], however
there is very little quality evidence regarding its thera-
peutic utility and safety in a primary care setting.
The aim of this manuscript is to outline and discuss
the results from a randomized controlled trial of the
biopsychosocial-based intervention, NET, for individuals
with primary hypothyroidism. This document has been
prepared using the CONSORT 2010 guide for the
reporting of parallel group randomized trials [67, 68], as
well as the associated documents for randomized trials
of non-pharmacological treatments [69], and the guide
to harms reporting [70].
Methods
The research presented in this manuscript was approved
by the Macquarie University Ethics Review Committee
(Reference no.: HE-27AUG2004-MO3136).
Design
Parallel, blinded, multi-centre (11 sites), randomized,
placebo-controlled, trial conducted from August 2006 –
March 2010. The study was designed to align with quality
recommendations set out in the PEDro scale [71] and The
Delphi list [72] as well as with the relevant CONSORT
guidelines available at the time of trial design [67, 69, 70,
73, 74].
Participants
The study team sought to recruit participants from the
Sydney Metropolitan area of Australia using advertise-
ments in a variety of hardcopy and electronic media.
Participants were randomized into either the NET group
or the placebo group after being screened for eligibility
by the chief investigator.
Inclusion criteria - participants
For inclusion, participants had to be ≥18 years of age and
have received a diagnosis of primary overt hypothyroidism
from a qualified medical practitioner or specialist. In long-
standing hypothyroidism there is pituitary thyrotroph
hyperplasia [75]. For this reason, it can take up to six
months for TSH levels to fall into normal ranges after the
initiation of LT4 therapy [76]. Based on this information,
if a respondent was taking medication, e.g. levothyrox-
ine, it was stipulated that they be on a stable dose of
this medication for at least six months before enrol-
ment into the trial. Acknowledging that treatment is
commonly initiated promptly after diagnosis, partici-
pants were only included in the trial if they had re-
ceived their diagnosis more than six months prior to
enrolment. Participants were not asked by the research
team to alter or cease their thyroid medication at any
point during the trial as this would be deemed unethical
given the experimental nature of the intervention. How-
ever, participants were asked to immediately report any
such changes to the chief investigator so that this informa-
tion could be incorporated into the interpretation of the
final results.
Exclusion criteria – participants
Participants who were <18 years of age were excluded.
Individuals with variants of hypothyroidism other than
primary overt hypothyroidism, such as hypopituitarism,
were excluded. This also included iatrogenic forms of
hypothyroidism. Individuals who were on medications
that could potentially impair thyroid function e.g. Lith-
ium were excluded. Participants who reported a history
of significant head or neck trauma/surgery/radiotherapy
were excluded, as were individuals with diagnosed ser-
ious psychological or physical co-morbidities. Females
who were pregnant or looking to conceive within the
trial period were excluded. As participants were required
to interact mentally and physically with the practitioner
during the intervention phase of the trial, those with
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cognitive or physical disabilities e.g. individuals who are
hard of hearing were excluded from the trial.
Inclusion criteria – practitioners
It was necessary that the practitioners applying the inter-
vention were well-versed with the NET procedure. Con-
sequently, practitioners were only included if they had
attained the maximum qualification available at the time
(‘Certification’ in NET) [77] and a minimum experience
of two years with the procedure. This ensured a high
degree of competency and also acted as a means of stan-
dardising the intervention. Practitioners were required
to be available for the full duration of the intervention
phase for each participant. Practitioners had to agree to
treat within the confines of the research methodology
and comply with the study protocol, which included the
application of a placebo intervention to the relevant par-
ticipants. The treating practitioners were asked to make
times available in their normal practice hours for the
treatment of the trial participants. There was no remu-
neration offered to the practitioners involved in the trial.
Inclusion criteria – research centres
The research was conducted at 11 private practices. To
be included as a research venue, the practice had to fulfil
several criteria: be located in the Sydney Metropolitan
area, have practitioners with the relevant training and
clinical expertise in NET, and be open at least two days
per week with capacity for both during and after-hours
business operations.
Intervention
The NET and placebo procedures have been described
in depth by several authors [63, 64, 78–84] and it is not
within the scope of this article to replicate this discus-
sion. A detailed version of the NET and placebo proto-
cols used in this trial was published in an open-access
journal in 2010 [85]. The treatment protocol used in this
study was also similar to that employed by Karpouzis et
al. [78] and Karpouzis [79].
The placebo treatment was developed by a panel that in-
cluded experts in NET and members of the research team.
The placebo intervention was designed to closely mimic
the NET intervention protocol but with the purported
therapeutic components removed and replaced with in-
nocuous steps.
Participants who were randomized to the intervention
group received ten NET treatments over a six week
period. Similarly, participants in the placebo group re-
ceived ten placebo treatments over the same period. Two
treatments per week were scheduled in the initial four
weeks and one treatment per week in the final two weeks
of the intervention phase. There was no further interven-
tion after this point. Each treatment, NET or placebo, went
for 5–20 min in duration. Participants attended the same
clinic and saw the same practitioner for all of their treat-
ments, all participants attended clinics that were closest to
their place of work or residence.
All practitioners involved in the trial were given a training
session by the chief investigator, and issued with an
information booklet detailing the steps involved with the
application of each individual arm of the intervention (NET
and Placebo). Practitioners were instructed to deliver the
placebo treatment with the same vigour and enthusiasm as
the NET treatment. Both practitioners and participants had
24-hour access to the chief investigator at all times during
the trial via a toll-free telephone number.
Outcomes
Several outcome variables were used to capture potential
psychological and/or physiological changes that may
have coincided with the application of therapy.
Primary outcome
The primary outcome was the change in depressive states
at 7 weeks and 6 months using the Depression, Anxiety,
Stress Scale (DASS-42) [86]. The normal range for states of
depression is between zero and nine points, with scores
greater than nine indicating high states of depression. States
of depression was chosen as the primary outcome as it is
one of the most common neuropsychiatric symptoms
observed in primary overt hypothyroidism, and it is a com-
monly reported symptom in individuals with continued
symptomatology despite normalised thyroid function tests.
Secondary outcomes
Although it was anticipated that many of the partici-
pants would be entering into the trial with pre-existing
management plans, i.e. thyroid hormone replacement
schedules, it was prudent that thyroid function tests be
added to the list of outcomes. The thyroid function
tests included the serum measurement of thyroid
stimulating hormone (TSH), free-thyroxine (FT4) and
free-triiodothyronine (FT3) concentrations. The nor-
mal reference range used in this research for TSH was
0.40–3.50 mIU/L and the assay calibration range was
0.00–100.00 mIU/L [87]. The normal reference range
used in this research for FT4 and FT3 was 9.0–19.0
pmol/L and 2.6–6.0 pmol/L respectively. The calibra-
tion range for the FT3 and FT4 assays was 0.000–9.216
pmol/L and 0.00–77.22 pmol/L respectively [88, 89].
In addition to the thyroid function tests, serum concen-
trations of antibodies to thyroid peroxidase (TPO-Ab) and
thyroglobulin (Tg-Ab) were also measured. The normal
reference range for TPO-Ab was 0–35 mIU/L, and the
normal reference range for Tg-Ab was 0–40 mIU/L.
The calibration range for the TPO-Ab and the TG-Ab
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assays was 0.0–1000.0 mIU/L and 0.0–3000.0 mIU/L
respectively [90, 91].
The remaining items on the DASS-42 questionnaire,
states of anxiety and stress, were assessed (Normal Range:
Anxiety 0–7, and Stress 0–14). Scores outside of the nor-
mal reference range indicate abnormal states.
The Short Form-36 version two (SF-36v2) questionnaire
[92] was also included in the list of secondary outcomes.
The mean score for a normal population for the domains
and component summary scores is 50 norm-based scoring
points with a standard deviation of 10 points. High scores
on the SF-36v2 represent high functioning whereas scores
below the normal mean indicate poorer function.
In addition to the DASS and SF-36v2 questionnaires,
participants were instructed to measure their resting
heart rate (RHR) (radial pulse method) and resting
temperature (RT) at a set time each day and record this
data in a diary provided by the researchers. The normal
ranges for RHR used for this trial were 75–85 bpm.
Participants measured their RT by placing a digital therm-
ometer in their axilla for approximately one minute. The
normal reference range for resting temperature used in
this research was 35.5–37 °C.
The aim with each of these primary and secondary
outcomes measures was to examine the change in each
measure at 7 weeks and 6 months to determine whether
there was evidence that NET was different (efficacious)
compared to placebo. This schedule would allow for the
detection of any slow adaptations of the Hypothalamic
Pituitary Thyroid axis in response to any short term
(7 weeks) and medium term (6 months) benefit derived
from the NET intervention.
Schedule of assessments
Baseline measurements were taken for both the primary
and secondary outcomes. Thyroid function tests and
thyroid auto-antibody measurements were performed at
commercial pathology facilities approximately one week
before the commencement of the intervention. The
DASS, SF-36v2, and a demographic questionnaire were
issued and completed by participants at the respective
clinic just prior to the initial treatment. The first follow-up
assessment was performed at seven weeks which included;
a thyroid function test, serum thyroid auto-antibody
measurements, and the DASS and SF-36v2 question-
naires. A second follow-up assessment was performed
at six months which was identical to the one performed
at seven weeks only with the addition of a health up-
date questionnaire (HUQ) (Appendix). The HUQ was
designed by the research team to capture any changes
in a participant’s health status, i.e. changes in medica-
tion, lifestyle, or major life events in the previous six
months that may have influenced the final results and
the associated interpretation. The daily home recording
of RT and RHR commenced one week before the inter-
vention phase and continued for the full duration of a
participant’s enrolment in the trial.
Blinding survey
The chief investigator contacted each participant by
phone after the participant’s final results had been re-
ceived. The chief investigator thanked the participant for
their involvement in the trial and asked them to identify
which group, NET or placebo, they felt that they had been
allocated to. The participant’s response was recorded and
used to assess the adequacy of the blinding process.
Harms data
A combination of active and passive harms surveillance
was used in this study. Practitioners were required to
maintain clinical records for each participant visit dur-
ing the intervention phase. At the beginning of each
intervention session participants were asked by the
treating practitioner if they had experienced any ad-
verse events in the period that followed the last inter-
vention. Participants were also asked how they felt
directly after each intervention. Any responses to these
questions were detailed in the participants’ records. In
addition to the active harms surveillance participants
were also asked to contact the chief investigator if any
problems or difficulties arose using the toll free tele-
phone number. These two strategies, combined with
information from the HUQ, were used to capture any
adverse events that may have coincided with the appli-
cation of the intervention. These data were compiled
and used in the final interpretation of technique safety
by the chief investigator. Adverse events were defined
as an adverse consequence of the intervention (placebo
or NET) that occurred any time after the first interven-
tion. Classification of the event as being an ‘adverse event’
was determined by either the participant and/or members
of the research team.
Modifications to the trial protocol
There were several modifications made to the trial proto-
col between August 2006 and March 2010. In 2007, the
pathology company commissioned to analyse the serum
measures changed the methodology for analysing the
thyroid auto-antibody concentrations. This resulted in
the early auto-antibody measures being incompatible/
non-comparable to the newer measures. This change
prompted the research team to change the TPO-Ab
and the Tg-Ab from being continuous variables to
dichotomous variables (i.e. either ‘within’ the normal
reference range or ‘outside’ of normal reference range)
in the final analysis. This resulted in a loss of sensitivity
with respect to the minimal clinically important difference
detectable for this particular measure.
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As the measurement of TSH and FT4 is the standard
‘first-line’ test for individuals with thyroid dysfunction, there
were several instances in which the pathology company,
due to internal protocols, did not measure the FT3 or thy-
roid auto-antibody concentrations. Many of these cases
were picked up by the chief investigator, however there
were instances in which the participant’s sample was
destroyed before the chief investigator was able to notify
the pathology company of the omission. This resulted in six
participants having only partial data for certain variables.
This remains a limitation of the study.
As the trial was run over a four year period, there
were several changes in the line-up of treating practi-
tioners. Four practitioners started out in 2006. Eight
more practitioners were recruited between 2006 and
2010, and four practitioners ceased their involvement
in the study during this period due to personal reasons.
Despite these changes, each participant received their
intervention from a single practitioner.
Sample size
A two-sided, power-analysis indicated that 51 participants
per group would yield a greater than 80 % chance of de-
tecting a difference in depression scores of at least four
points in the NET group compared to placebo group using
a standard deviation of 6.97 based on normative data
[86, 93]. A four point reduction in depression scores, as de-
fined by the DASS-42, would represent a clinically mean-
ingful reduction in states of depression. The ranges for
the depression scale are: normal 0–4, mild 5–6, moderate
7–10, severe 11–13 and extremely severe 14+ [86].
Stopping guidelines
Guidelines were set that dictated that the trial would be
stopped in the event of serious adverse events occurring
in participants during their participation in the trial.
Randomization
A simple randomization technique was employed. A
random sequence generator [94] was used to produce a
random sequence with no repeats. These numbers were
then recorded on individual pieces of paper and placed
into opaque envelopes which were then sealed. After
each consenting participant completed their initial
blood test an envelope was selected for that participant
by the chief investigator. Participants allocated an even
number were assigned to the NET group, and those
receiving an odd number were assigned to the placebo
group. The chief investigator, practitioners and other
researchers remained naive to a participant’s group
allocation until just before the application of the
intervention.
Blinding
Pathology company staff and any primary care provider/s
involved in the participant’s non-trial management (e.g.
the participant’s general practitioner or endocrinologist)
were blinded to the group allocations. The allocation of
individual participants to treatment groups was con-
cealed to the chief investigator up until the point of a
participant commencing treatment. Practitioners were
notified of each participant’s group allocation prior to
performing the intervention and were instructed not to
reveal the allocation to the participant. Individual par-
ticipants were not told their group allocation until the
end of their involvement in the trial and after the com-
pletion of the blinding survey (Table 1).
Statistical procedures
The R software program [95] was used to conduct all
the analyses. Linear mixed-effects (LME) models were
employed for all continuous outcome measures except
for the thyroid antibody concentrations. Linear mixed-
effects models utilise all available data to provide un-
biased estimates of the mean difference between groups
in the presence of missing at random data and hence
form an intention to treat (ITT) analysis [96]. Since
these are more widely used methods, the imputation
techniques and statistical methods described in the ori-
ginal protocol were not conducted. The thyroid antibody
measures had been dichotomised and logistic mixed-
effects models were the planned analysis technique.
However model convergence issues meant that it was
necessary to calculate unadjusted odds ratios with 95 %
confidence intervals for each time point instead. The
final data set was screened for errors prior to all ana-
lyses. P-values for the interaction and pairwise difference
at each time point have been presented for each out-
come measure together with 95 % confidence intervals
(CI). All participants were analysed according to their
initial group allocation. A sensitivity analysis was con-
ducted by adjusting for baseline differences between
groups by using baseline data as a covariate in the
mixed-effects model. However, the effect of this was that
Table 1 Trial timeline. The trial timeline depicts the timing of all
interventions and outcomes measured during the trial
Shaded Area = Event occurrence, DASS depression anxiety stress scale, SF-36v2
short form 36 version 2
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cases with missing baseline data were excluded from the
analysis and the analysis may no longer be considered
ITT. Demographic characteristics of participants were
summarised using frequency tables. Summary values
(mean, median, minimum, maximum, and standard de-
viation) for each group were used for the discussion of
baseline group equivalence. Fisher’s exact test was used
to analyse the results of the blinding survey. Two-
sided tests with a significance level of 5 % were used
throughout all analyses. No corrections (e.g. Bonferroni
method) were made to the significance level to adjust
for multiple testing due to the exploratory nature of the
secondary analyses.
Results
Post-randomization losses to follow-Up and protocol
deviations
The dropouts and protocol deviations that occurred at
various phases of the trial are detailed in Fig. 1.
Not all participants in the NET group received the full
ten treatments. The reasons for these protocol deviations
were either: personal reasons (1/44), administrative error
(5/44), the deterioration of a pre-existing medical condi-
tion (1/44), minor reaction to treatment (1/44), other time
commitments (1/44), and undisclosed reason/s (2/44).
With regards to outcome measures, the main reasons for
missing data were administrative errors at the private
clinics or the pathology company. Several participants in
the NET and placebo groups found the daily recording of
heart rate and temperature inconvenient and cumber-
some. As a result, there was incomplete compliance with
the recording of these outcomes.
Not all participants in the placebo group received the
full schedule of interventions or completed the full
complement of outcomes. The reasons for these devia-
tions were: work issues (1/46), expenses associated
with travel to the clinic location (1/46), undisclosed
reason/s (5/46), dissatisfaction with the placebo
intervention (3/46), other time commitments (1/46),
non-compliance with the trial protocol (5/46), and
administrative error (4/46).
Dates of recruitment
Recruitment for the clinical trial took place between
August 2006 and March 2010. Two hundred and forty
five individuals responded to the advertisements for par-
ticipation. Eligible consenting participants were followed
for six months after randomization.
Trial closure
A strict external schedule (stopping rule) was imposed
that meant that the trial must be commenced and
completed between August 2006 and October 2010
due to the length of the chief investigator’s PhD
candidature. No interim analyses were performed and
hence the decision to close the trial was independent
of the trial outcomes. The prescribed schedule meant
that no further participants could be recruited after
March 2010 despite needing additional participants to
fulfil the sample size target.
Baseline participant data
The demographic information and the mean baseline
clinical characteristics for participants are presented in
Tables 2 and 3 respectively. The two groups were very
similar with respect to demographic data. A compari-
son of the baseline clinical data is presented below.
Primary outcome - baseline
Boxplots of baseline depression scores are depicted in
Fig. 2. The mean and median depression scores for the
placebo group were within normal range, however the
mean score for the NET group fell just outside of the
normal range. A large proportion (19/44) of participants
in the NET group and 15/46 participants in the placebo
group reported states of depression that fell outside of
the normal range at the time of initial testing.
Secondary outcomes and clinical data - baseline
With respect to baseline clinical data, the mean TSH
scores for the NET group were skewed by one individ-
ual with an extremely high TSH value that remained
high at the subsequent seven week and six month reas-
sessments. With reference to thyroid autoimmunity,
30/44 participants in the NET group demonstrated
higher than the normal concentrations of TPO-Ab and
12/44 demonstrated higher than normal concentrations
of Tg-Ab. Similar results were seen in the placebo
group with 30/46 and 14/46 of participants demon-
strating abnormally high TPO-Ab and Tg-Ab concen-
trations respectively.
With respect to the additional DASS items, 17/44 of
the NET group and 10/44 of the placebo group re-
ported anxiety scores in the mild to severe range. A
considerable proportion of the trial participants also
reported mild to extremely severe stress scores (NET
19/44, Placebo 13/44).
The mean baseline scores for the SF-36v2 questionnaire
revealed that the trial participants had lower mean
self-reported general health (NET 11/44, Placebo 9/46),
vitality (NET = 21/44, Placebo 23/46) social functioning
(NET 9/44, Placebo 11/46) and mental health (NET 8/44,
Placebo 10/46) compared to normative data.
Resting temperature was comparable and within normal
range at baseline for both the NET and placebo groups.
The data regarding heart rate highlight that the majority
of participants in both the NET and placebo groups had
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Fig. 1 Participant flow diagram. DASS = Depression Anxiety Stress Scale, HUQ = Health Update Questionnaire, NET = Neuro-Emotional Technique,
SF-36v2 = Short Form 36 Version 2, TFT = Thyroid Function Test, Min = Minimum, Max =Maximum, IQR = Interquartile Range
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lower than normal heart rate compared to the normal
range (NET = 37/44, Placebo 44/46).
In addition to the primary and secondary outcomes re-
searchers also gathered data on the previous use of psy-
chological services and concurrent use of medications
and/or nutritional supplements. Thirty four percent (15/
44) of the NET group and 37 % (17/46) of the placebo
group reported that they had used support services (e.g.
counselling service) in the past for emotional, psycho-
logical or lifestyle problems. At baseline, the vast majority
of participants (NET 40/44, Placebo 43/46) reported cur-
rently using some form of thyroid medication for the
treatment of their condition. With respect to additional
medication use, 21/44 of participants in the NET group
and 20/46 of participants the placebo group reported
using medications other than those prescribed for their
thyroid condition. A substantial proportion of trial partici-
pants (NET 28/44, Placebo 27/46) reported taking nutri-
tional products or supplements.
Analysis
The results from the linear mixed-effects modelling for
the primary outcome may be seen in Table 4 and Fig. 3.
Secondary outcomes that comprised of continuous data
are presented in the remaining rows of Table 4. There was
no significant interaction between time and treatment
group for any of the outcome variables included in the
study (final column of Table 4) indicating that there was
no evidence of a difference between groups over time
(Fig. 3 Primary outcome). There were no significant differ-
ences, at the 5 % significance level, between the NET and
placebo groups at time seven weeks or six months (see the
3rd and 6th columns of Table 4) for any of the primary or
secondary outcomes.
There were no significant differences between the
NET and placebo groups for either RHR (p = 0.20) and
RT (p = 0.18) readings over time.
The odds ratios and 95 % confidence intervals indicated
no significant differences, at the 5 % significance level, be-
tween groups in the odds of demonstrating Tg-Ab con-
centrations outside of reference range at the seven weeks
(OR: 0.65, 95 % CI: 0.24 to 1.73, p = 0.38) or the six month
(OR: 1.24, 95 % CI: 0.45 to 3.38, p = 0.68) time points.
Similar outcomes were observed with TPO-Ab concentra-
tions (7 week OR: 0.94, 95 % CI: 0.32 to 2.74, p = 0.90;
6 month OR: 0.69, 95 % CI: 0.25 to 1.92, p = 0.48).
Sensitivity analysis was undertaken by using baseline
outcome as a covariate in each of the continuous outcome
models shown in Table 4. While the baseline value was
consistently a highly significant factor (p < 0.0001), the
interaction between time and group remained non-
significant for all outcomes (p > 0.3). In other words, the
only differences between groups, were those differences
observed at baseline with no significant change over time.
Harms/adverse events
The harms/adverse events section has been written in ac-
cordance with the CONSORT document for the better
reporting of harms in randomized trials [70]. No validated
harms recording instruments were used.
Adverse events - NET group
Six (14 %) participants in the NET group reported ad-
verse events that coincided with the application of inter-
vention. One participant in the NET group reported
feeling “sad” after the fifth treatment session. This same









Standard Deviation 11.21 11.32
Number of children Mean 1.51 1.81
Standard Deviation 1.30 1.20
Gender Female 43 40







Birthplace Australia 26 29
Highest level of
education












Employment Full-Time 17 16
Part-Time 11 13
Retired 13 11
Not Working 2 4
Unknown 1 2
HSC higher school certificate, TAFE technical and further education
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Table 3 Mean baseline clinical characteristics
Outcome measure Treatment Placebo
Normal range Median (Min, Max) Mean (SD) Median (Min, Max) Mean (SD)
Thyroid function tests:
TSH (mIU/L) 0.40–3.50 0.96 (0.00, 55.77) 2.98 (8.39)a 1.34 (0.01, 7.30) 1.85 (1.76)
FT4 (pmol/L) 9.0–19.0 15.00 (7.00, 26.00) 15.09 (3.22) 14.20 (3.80, 24.50) 14.51 (3.91
FT3 (pmol/L) 2.6–6.0 4.06 (2.80, 7.45) 4.13 (0.80) 3.80 (3.00, 5.73) 3.95 (0.64)
DASS Scores:
Depression 0–9 6.50 (0.00, 29.00) 9.43 (8.60) 6.00 (0.00, 41.00) 7.85 (8.52)
Anxiety 0–7 6.00 (0.00, 19.00) 6.79 (5.13) 4.00 (0.00, 30.00) 6.27 (7.73)
Stress 0–14 13.00 (3.00, 35.00) 13.71 (8.28) 11.00 (2.00, 38.00) 12.76 (8.53)
SF-36v2 Scores: Normal Mean (SD) Median (Min, Max) Mean (SD) Median (Min, Max) Mean (SD)
Physical functioning 50 ± 3 (10) 52.82 (25.46, 57.03) 48.06 (8.36) 50.72 (29.68, 57.03) 48.66 (7.72)
Role physical 50 ± 3 (10) 49.51 (22.57, 56.85) 48.85 (8.60) 51.96 (17.67, 56.85) 46.32 (11.25)
Bodily pain 50 ± 3 (10) 46.06 (24.08, 62.12) 49.97 (9.87) 46.06 (24.08, 62.12) 46.53 (9.43)
General health 50 ± 3 (10) 45.31 (23.38, 57.70) 43.72 (11.26) 45.78 (23.78, 62.47) 45.16 (9.71)
Vitality 50 ± 3 (10) 39.60 (23.99, 58.33) 40.15 (8.88) 41.16 (20.87, 58.33) 41.68 (10.33)
Social functioning 50 ± 3 (10) 45.94 (13.22, 56.86) 42.09 (12.49) 45.94 (13.22, 56.85) 41.12 (12.82)
Role emotional 50 ± 3 (10) 48.10 (20.89, 55.88) 44.78 (10.71) 44.22 (20.89, 55.88) 43.58 (10.96)
Mental health 50 ± 3 (10) 44.38 (21.85, 61.27) 43.79 (11.04) 47.19 (16.22, 58.46) 43.03 (11.62)
Physical component summary 50 ± 3 (10) 50.46 (30.08, 61.73) 48.27 (7.76) 51.39 (16.70, 59.78) 48.45 (9.54)
Mental component summary 50 ± 3 (10) 42.59 (16.70, 60.18) 41.10 (11.49) 41.59 (16.40, 61.35) 40.79 (12.71)
Normal Range Median (Min, Max) Mean (SD) Median (Min, Max) Mean (SD)
Resting temperature (°C) 35.5–37.03 35.8 (32.8, 37.0) 35.6 (0.9) 35.6 (33.4, 36.6) 35.6 (0.7)
Resting heart rate (bpm) 75–85 64 (30, 86) 65.7 (9.6) 64 (44, 86) 63.9 (11.3)
The SF-36v2 scores are based on the norm based scoring system (NBS) which is based on a mean score with a normal range between 47 and 53 NBS points. Resting temperature and resting heart rate data were
analysed based on ‘Day 1’ dairy entries
aStrongly influenced by one person with very high TSH
DASS Depression, Anxiety, Stress Score, NET Neuro-Emotional Technique, TSH Serum thyroid stimulating hormone, FT4 Free thyroxine, FT3 Free triiodothyronine, SF-36v2 Short Form-36 Version 2, Min minimum,













participant also described feeling “light-headed” after the
sixth treatment session. One participant described feel-
ing “drained” after the ninth treatment session. One par-
ticipant described the sensation of her “head spinning”
after the first treatment session. This same participant
reported “pain in the lower neck” after the second ses-
sion and reported a “light headed” feeling after treat-
ments three, four, six and nine. On treatment number
nine the participant reported “Always feeling a bit light
headed”. On visits seven and eight this same participant
reported feeling “tired”. One participant in the NET
group developed a sore throat during the middle of the
treatment phase which abated after two weeks. One
participant reported feeling “a bit sad” after the ninth
treatment session. One participant reported feeling “de-
pressed” after the first and second treatment sessions.
During the second treatment session, the participant
felt uncomfortable while discussing a memory from her
past that was prompted by the questioning associated
with the intervention. The participant reported that a
couple of hours after this treatment that she experi-
enced a migraine headache that lasted for several
hours. The participant was unhappy with the nature of
treatment and withdrew herself from the trial. The vast
majority of adverse events observed in the NET group
occurred directly after the application of the interven-
tion and were not reported at the time of subsequent
interventions indicating that these events were of a lim-
ited duration. The participants who did experience
adverse events did not require any treatment aside
from reassurance from the associated practitioner. No
adverse events were reported in the NET group during
the post-intervention phase of the clinical trial.
Adverse events - placebo group
Six (13 %) participants reported adverse events that coin-
cided with the application of the placebo intervention. Five
of the six described feeling “tired” directly after one or
more of the placebo intervention sessions. One participant
described feeling “sore” after the tapping applied by the
treating practitioner to the right inferior angle of the
scapula. No adverse events or harms were reported in
the placebo group during or after the post-intervention
phase of the clinical trial.
Blinding survey
Of the total number of participants that undertook the
blinding survey (n = 81), 10/41 (24 %) of placebo partici-
pants correctly assumed that they were allocated to the
placebo group. Two out of 40 (5 %) participants in the
NET group correctly assumed their assignment to the NET
group. There was a statistically significant difference
between these two proportions (Fisher’s exact test,
p = 0.025). Based on these results, participants in the
placebo group appeared more likely to correctly guess
their group allocation compared to individuals in the
NET group.
Fig. 2 Baseline depression scores
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Discussion
This is the first randomized controlled trial investigating
the short-medium term effects of NET treatment on in-
dividuals with primary hypothyroidism. Both treatment
effects and harms data were captured in this study with
the major findings presented below.
The NET and placebo groups were comparable with re-
spect to clinical and demographic data at baseline. The
vast majority of the study population were taking some
form of thyroid medication, most commonly LT4, for their
condition. The mean and median serum TSH, FT3, and
FT4 concentrations were within the normal range. The
Fig. 3 Depression scores over time
Table 4 Analysis of primary and secondary outcomes
Outcome MCID (±) Difference between groups 7 weeks
(NET-Placebo)




Mean difference (95 % CI) P-value Mean difference (95 % CI) P-value P-value
Depression 4 −0.58 (−4.62, 3.45) 0.78 −0.04 (−4.04, 3.96) 0.98 0.60
Anxiety 5 0.63 (−2.19, 3.46) 0.66 0.36 (−2.44, 3.16) 0.80 0.98
Stress 4 0.29 (−3.63, 4.21) 0.88 1.47 (−2.42, 5.35) 0.46 0.86
TSH 0.75 0.11 (−2.64, 2.88) 0.93 1.01 (−1.76, 3.77) 0.47 0.49
FT4 6.0 0.67 (−0.81, 2.15) 0.37 0.33 (−1.14, 1.80) 0.66 0.85
FT3 1.5 0.29 (−0.24, 0.83) 0.28 0.15 (−0.38, 0.68) 0.58 0.82
Physical functioning 3.5 −0.76 (−9.07, 7.56) 0.86 1.75 (−6.41, 9.91) 0.67 0.35
Role physical 3.2 4.25 (−7.31, 15.81) 0.47 4.35 (−6.93, 15.63) 0.45 0.99
Bodily pain 4.5 3.56 (−7.62, 14.73) 0.53 2.35 (−8.43, 13.13) 0.67 0.76
General health 5.7 2.11 (−8.20, 12.43) 0.69 3.35 (−6.78, 13.47) 0.52 0.28
Vitality 5.5 0.27 (−9.76, 10.30) 0.96 −0.10 (−9.84, 9.65) 0.98 0.76
Social functioning 5.0 9.05 (−4.55, 22.66) 0.19 5.58 (−7.54, 18.69) 0.40 0.65
Role emotional 3.8 2.12 (−8.72, 12.96) 0.70 1.13 (−9.36, 11.61) 0.83 0.86
Mental health 5.5 4.73 (−5.23, 14.72) 0.35 4.83 (−4.84, 14.49) 0.33 0.65
Mental component summary 3.1 4.11 (−1.58, 9.79) 0.16 0.22 (−5.25, 5.69) 0.94 0.36
Physical component summary 3.8 1.02 (−3.14, 5.18) 0.63 0.97 (−3.10, 5.03) 0.64 0.50
MCID minimal clinically important difference, TSH thyroid stimulating hormone (mIU/L), FT4 free thyroxine (pmol/L), FT3 Free triiodothyronine (pmol/L)
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majority of participants displayed abnormal TPO-Ab
concentrations at baseline indicating the presence of
thyroid autoimmunity. The mean and median depression
scores were within normal range however, a substantial
proportion of participants displayed abnormal depression
scores at baseline. A similar scenario was observed with
respect to the anxiety and stress scores at the time of the
initial assessment. For the SF-36v2 data, mean self-
reported general health, vitality, social functioning, and
mental health scores were lower in the study population
compared to normative data. These baseline neuropsychi-
atric findings were expected given the continued symp-
tomatology reported large community based samples of
patients with treated hypothyroidism [14, 16, 23].
The results of the analyses revealed that there were no
significant differences, at the 5 % significance level, be-
tween the NET and placebo groups at time seven weeks
or six months for any of the trial outcomes.
If NET has a stress-reducing effect, either; this has not
been demonstrated in this particular study; or stress may
not be a salient factor in onset and/or progression of this
chronic disease. Further research, with much larger sample
sizes, is required to ascertain the exact role of stress in the
pathogenesis and progression of primary hypothyroidism.
With respect to harms, the way in which the NET
treatment was applied, including the dosage, was well-
tolerated by the study participants. There were some
minor, short-lived adverse-events that followed the ap-
plication of both the NET and placebo interventions.
Strengths of the study
This is the first RCT investigating the short-medium term
treatment effects of NET in participants with primary
hypothyroidism. Practitioners of varying backgrounds with
similar clinical expertise in NET applied the intervention to
the cohort. The approach to delivery, as well as the dosage
of the intervention was based on a private practice model
of care. The typical participant in the trial was a Caucasian
female with a mean age of 45 years, with evidence of
thyroid autoimmunity. This profile aligns strongly with
epidemiological data regarding patients with primary
hypothyroidism [3, 8, 97]. Due to the systemic influence of
the thyroid hormones a wide selection of outcome mea-
sures were employed that would have captured any short-
medium term physiological and psychological changes that
coincided with the application of the intervention.
Limitations
Designing placebo interventions can be difficult in re-
search when the underlying biological mechanism behind
the therapy is unknown [98]. For this reason, designing a
placebo in complementary and alternative medicine re-
search is often dependent on unsubstantiated assumptions
about the specificity of the intervention [99]. With this in
mind, the placebo was designed via the collaboration of a
group of NET certified practitioners, and members of the
research team. The aim was to create a placebo interven-
tion that would: closely mimic the NET intervention;
would not provide any therapeutic benefit; would be con-
sidered credible by the participants; and would be of com-
parable duration to the NET procedure. The results from
the analysis of the blinding survey results would suggest
that the placebo intervention was more likely to be viewed
as a ‘sham’ procedure compared to the NET treatment. As
the practitioners were involved in the administration of
both the NET and placebo interventions, it was not pos-
sible to blind these individuals to group allocation. How-
ever, to reduce the problem of non-blinding, practitioners
were under strict instruction not to reveal group allocation
to participants during the trial, and also to refrain from
discussing any of the procedures in detail. Furthermore, as
the treatment being provided by the practitioners in their
private clinics was not recorded or monitored it was not
possible to guarantee the fidelity of either of the treatment
arms. Slight differences in the delivery of the NET and pla-
cebo intervention may account for the results observed in
the blinding survey.
The participant’s subjective report regarding reactions
or adverse events associated with the intervention had
the potential to be selectively-filtered by the treating
practitioners. The majority of practitioners involved in
the trial regularly use NET in their private clinics. These
practitioners would presumably want to demonstrate the
efficacy and safety of the intervention which may have
introduced performance and/or reporting bias.
The study was designed to explore the influence of a
biopsychosocial-based treatment approach on the clinical
manifestations of primary hypothyroidism. The approach
involved a diverse number of outcome measures, and
multi-centre format in order to make use of all available
resources. This scenario can be problematic in that it in-
troduces the statistical problem of multiple comparisons
in which the chances of obtaining a false positive result
are increased [100]. While no corrections for multiple
testing were used given the exploratory nature of the
secondary outcomes this type of correction would not
have changed the results obtained in this study.
A power analysis indicated that 51 participants per
group would yield a more than 80 % chance of detecting a
difference in depression scores of at least four points in
NET group compared to the placebo group using a stand-
ard deviation of 6.97 based on normative data. The fact
that the recruitment of participants fell short of the de-
sired sample size means that there is reduced power to
find a difference between groups. If we examine how many
participants in each group achieved a four point decrease
in depression scores at 7 weeks (11/22 for NET vs 7/18 for
placebo) then a 95 % confidence interval for the number
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needed to treat before a positive treatment outcome oc-
curred would be (−19 to 29). This wide interval indicates
anything from no benefit to benefit for 1 in 29 participants
and reflects the uncertainty in the data collected.
The sample that was obtained aligns well with profiles
from large population studies regarding patients with
primary hypothyroidism. There is however the potential
that a specific type of participant responded to the re-
cruitment advertisements. As the advertisements were
calling for participation in research investigating a new,
drug-free treatment for hypothyroidism, it is possible
that individuals who were either: not taking medication;
opposed to the concept of taking medication; poorly
compliant with their current medication regimens; or
dissatisfied with their current management regimens
were more likely to respond. Furthermore, the advertise-
ments made reference to the Department of Chiroprac-
tic at Macquarie University, as the host of this research.
Proponents of chiropractic/complementary and alterna-
tive medicine, or individuals with positive past experi-
ences with chiropractic treatment may therefore have
been over represented in the sample population.
Both the DASS-42 and the SF-36v2 have recall periods
of less than one month. For this reason, treatment ef-
fects with long latency periods may have been missed in
between the seven-week and six-month assessments.
Dr Scott Walker [101], the creator of NET, originally de-
signed the technique to be an adjunct to the usual manual
therapy procedures he was using in his private practice.
Walker deemed psychosomatic stress to be an important
factor contributing to continued or cyclical symptomatol-
ogy in his patients and designed NET to tackle this prob-
lem. The technique represented an additional tool that a
practitioner could use if the standard manual procedures
alone were not having a longstanding therapeutic effect in
patients with musculoskeletal conditions [102]. Later on
in the development of NET, Walker added nutritional ele-
ments and aspects of homeopathy to the NET procedure.
In an attempt to make the investigation of NET more
manageable, and the results from the study more compre-
hensible, the research team restricted the intervention to
only the component of NET that deals with psychosocial
stress. Based on reviews of homeopathy trials, the magni-
tude and plausibility of treatment effects of homeopathy
for specific medical conditions remains poorly defined
[103–105]. In a recent report from the National Health
and Medical Research Council of Australia a working
committee concluded that there were no health conditions
for which there is reliable evidence that homeopathy is ef-
fective [106]. In the latest guidelines for the management
of hypothyroidism, produced by the American Thyroid As-
sociation Taskforce, strong recommendations were made
against the use of dietary supplements and nutraceuticals
[12]. The main reasons for these recommendations were A)
the lack of evidence regarding the efficacy of these products
and B) the potential risks associated with the use of these
products for individuals with thyroid conditions. There is a
dearth of high quality evidence regarding manual therapy
for the treatment of hypothyroidism and a limited
evidence-base for homeopathy and nutrition in this role. It
is therefore difficult to ascertain what effect removing these
components may have had on the overall efficacy of the
NET procedure.
As stress is a potential environmental risk factor for the
development of primary hypothyroidism, it is possible that
NET treatment, a purported stress reduction technique,
may function better in a preventative role. In cases of long
standing autoimmune thyroid disease there is inflamma-
tion and subsequent destruction of the thyroid follicles.
This results in the replacement of the thyroid parenchymal
tissue with non-functional fibrous tissue [107]. In this
scenario, the pathophysiological consequences of auto-
immune thyroid disease have resulted in tissue that no
longer has an endocrine function. While the disease
process and the associated symptomatology continues, the
damaged tissue is unlikely to respond, from an endocrine
perspective, to any therapeutic intervention. To determine
the preventative effect of NET treatment would require a
large scale preventative trial which currently lacks eviden-
tial support and is beyond the scope of this discussion.
In obtaining ethics approval for this study researchers
were required to outline the foreseeable risks associated
with participation in the study. At the time of the trial de-
sign there were no published harms data regarding NET.
As a result, an information and consent form was drafted
that included likely potential adverse events such as
muscle soreness, tiredness, and an uncomfortable recall of
past events. These events were suggested as potential out-
comes during consultation with experts in NET. While
there were some minor adverse events that coincided with
the intervention in both the NET and placebo groups,
there is the possibility that participants were primed [108]
to report certain events due to the content of this informa-
tion and consent form.
Conclusions
In this study, NET intervention was not found to confer
any clinical benefit to the participants in the short or
medium term.
The data recorded on harms suggest that there are
some minor, short-term, adverse events associated with
the application of this procedure. These events however
were predictable, relatively innocuous and did not re-
quire further intervention to remedy.
Appendix
Health update questionnaire
Name: ________________________ Date: _____________
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There are events and situations that occur in our
lives that can influence our health and well-being.
When running a clinical trial it is important for re-
searchers to be aware of any events or situations that
may influence the findings of the trial.
This questionnaire is designed to identify any factors
that may influence the findings of the trial, and hence
influence the final interpretation of results.
We ask that you fill out the questionnaire as accurately
as possible. This information, when combined with the
data obtained from initial and subsequent assessments,
will help researchers accurately interpret the findings at
the end of the trial.
Q1) Have you changed your medication or changed
the way in which you are managing your condition
(Hypothyroidism) in the last 6 months since beginning
the trial? (Please circle one)
Yes No
If so, what have you changed?
_______________________________________________
_________________________________________________
Q2) Have you tried any other forms of treatment for
your condition in the last 6 months since beginning the
trial? (Please circle one)
Yes No
If so, what have you tried?
_______________________________________________
_________________________________________________
Q3) Have there been any major stressful situations or
events in the last 6 months that may have influenced
you general health and well-being? (Please circle one)
Yes No
If so, what were these situations or events? (Optional)
_______________________________________________
_________________________________________________
Q4) Have you made any significant alterations to your
life or your lifestyle in the last 6 months since beginning
the trial? (Please circle one)
Yes No
If so, what alterations have you made? (Optional)
_______________________________________________
_________________________________________________
Thank you for taking the time to fill out this
questionnaire
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